Daily Anesthesiology Research Analysis
Across three rigorous trials, perioperative and pain management practices are directly informed. A multicenter RCT in Lancet found no benefit of evolocumab for 24‑month saphenous vein graft patency after CABG despite substantial LDL-C lowering. A double-blind RCT optimized pulsed radiofrequency duration at the dorsal root ganglion for lumbar radicular pain, and a randomized trial in cardiac surgery supports remimazolam as an effective sedative alternative to propofol.
Summary
Across three rigorous trials, perioperative and pain management practices are directly informed. A multicenter RCT in Lancet found no benefit of evolocumab for 24‑month saphenous vein graft patency after CABG despite substantial LDL-C lowering. A double-blind RCT optimized pulsed radiofrequency duration at the dorsal root ganglion for lumbar radicular pain, and a randomized trial in cardiac surgery supports remimazolam as an effective sedative alternative to propofol.
Research Themes
- Perioperative cardiovascular therapy and graft outcomes after CABG
- Optimization of neuromodulation parameters for chronic radicular pain
- Sedation strategy and safety in cardiac anesthesia
Selected Articles
1. Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial.
In 782 randomized CABG patients, evolocumab achieved a ~48% placebo-adjusted LDL-C reduction at 24 months but did not reduce the saphenous vein graft disease rate compared with placebo (21.7% vs 19.7%; p=0.44). The therapy was well tolerated. These findings indicate further LDL-C lowering does not meaningfully influence mechanisms driving early SVG failure.
Impact: A large multicenter double-blind RCT directly challenges the assumption that more intensive LDL lowering improves early SVG outcomes after CABG.
Clinical Implications: Do not expect early evolocumab initiation after CABG to improve 24‑month saphenous vein graft patency; prioritize other graft-protective strategies (surgical technique, conduit choice, antiplatelet therapy).
Key Findings
- Placebo-adjusted LDL-C reduction of 48.4% at 24 months with evolocumab.
- No reduction in 24‑month vein graft disease rate: 21.7% (evolocumab) vs 19.7% (placebo); p=0.44.
- Adverse event profiles were similar, indicating good tolerability.
Methodological Strengths
- International, multicenter, randomized double-blind, placebo-controlled design
- Objective imaging-based endpoint (CCTA or invasive angiography) with prespecified analysis
Limitations
- Primary outcome data available in a subset of randomized participants (modified ITT analysis)
- Trial powered for graft disease rate, not for clinical events
Future Directions: Investigate non-lipid mechanisms of early SVG failure (e.g., intimal hyperplasia, thrombosis, graft handling) and evaluate targeted interventions beyond LDL lowering.
BACKGROUND: Saphenous vein graft (SVG) failure remains a substantial challenge after coronary artery bypass graft (CABG). LDL cholesterol (LDL-C) is a causal risk factor for atherosclerosis, but its role in SVG failure is not well established. We evaluated whether early initiation of intensive LDL-C lowering with evolocumab could reduce SVG failure. METHODS: NEWTON-CABG CardioLink-5 was a multicentre, double-blind, randomised, placebo-controlled trial conducted at 23 sites in Canada, the USA, Australia, and Hungary. Eligible participants were adults (age ≥18 years) who underw
2. Efficacy of pulsed radiofrequency treatment duration to the lumbar dorsal root ganglion in lumbar radicular pain: a double-blind randomized controlled trial.
In 60 patients with unilateral lumbar radicular pain, 6-minute DRG pulsed radiofrequency produced the most consistent, statistically significant pain and disability improvements versus 4 minutes at 6 months. Eight minutes showed additional subjective benefits (GPE) and per-protocol pain advantages. PRF was safe and well tolerated.
Impact: Provides parameter-level optimization from a double-blind RCT, directly translatable to procedural pain practice.
Clinical Implications: Adopt a 6-minute PRF duration for DRG targeting in lumbar radicular pain as a clinical standard; consider 8 minutes in selected patients prioritizing subjective benefit while balancing procedure time.
Key Findings
- Six-minute PRF reduced pain more than 4 minutes at 6 months (mean difference −1.35 NRS; p=0.031).
- All groups improved over time in NRS and ODI; 8 minutes showed lowest ODI and significant GPE improvement within-group.
- Per-protocol analysis confirmed superior pain reduction for 6 and 8 minutes versus 4 minutes.
Methodological Strengths
- Double-blind randomized controlled design with ITT and per-protocol analyses
- Multiple clinically relevant endpoints (pain, disability, global perceived effect) with 6-month follow-up
Limitations
- Modest sample size limits subgroup analyses and precision
- Single-condition focus; generalizability to other radicular levels or etiologies uncertain
Future Directions: Evaluate durability beyond 6 months, cost-effectiveness, and patient selection criteria for choosing 6 vs 8 minutes (e.g., baseline pain severity, sensory profiles).
BACKGROUND: Pulsed radiofrequency (PRF) of the dorsal root ganglion (DRG) is a minimally invasive treatment for lumbar radicular pain (LRP), but the optimal stimulation duration remains uncertain. Preclinical evidence suggests that extended PRF may enhance neuromodulation, yet comparative clinical data are limited. This randomized, double-blind controlled trial aimed to compare the efficacy according to duration of PRF of DRG in patients with LRP. METHODS: A total of 60 patients with chronic unilateral LRP were allocated to receive PRF of the DRG for 4 min (group A), 6 min (group B) or 8 min (group C). The primary outcome was pain intensity, measured by the Numeric Rating Scale (NRS) assessed at 1 week, 2 weeks, 1 month, 3 months, and 6 months. Secondary outcomes included functional disability (Oswestry Disability Index, ODI) and patient satisfaction (Global Perceived Effect, GPE) assessed at 1 month, 3 months and 6 months. The primary analysis followed an intention-to-treat (ITT) approach with the last observation carried forward. A per-protocol (PP) analysis was also conducted to validate results. RESULTS: All groups demonstrated significant improvement in NRS and ODI over time (p<0.001). At 6 months, group B showed significantly greater pain reduction compared with group A (mean difference=-1.35, SE=0.69, p=0.031). Group C also showed improved NRS and the lowest ODI scores, though not statistically significant in the ITT analysis. However, PP analysis revealed statistically significant NRS reduction in both groups B and C compared with group A. Group C was the only group to demonstrate significant within-group improvement in GPE over time. CONCLUSIONS: A 6 min PRF duration provided the most consistent and statistically significant improvement in pain and function, supporting its use as a clinical standard. The 8 min duration may yield additional subjective and functional benefits in selected patients. PRF was safe and well tolerated across all groups.
3. Remimazolam besylate versus propofol as sedative agents in cardiac surgery: A randomized noninferiority clinical trial.
In 318 analyzed elective cardiac surgery patients on CPB, remimazolam achieved a significantly higher protocol-defined sedation success rate than propofol (99.4% vs 82.3%; absolute difference 17.1%, p<0.001), meeting noninferiority. Recovery metrics and ICU/hospital length of stay were comparable.
Impact: First randomized evidence in cardiac anesthesia indicating remimazolam can reliably maintain intraoperative sedation targets with high success.
Clinical Implications: Remimazolam is a viable alternative to propofol for CPB cardiac surgery sedation, potentially offering more consistent target BIS maintenance without prolonging extubation or LOS.
Key Findings
- Protocol-defined sedation success was higher with remimazolam (99.4%) vs propofol (82.3%); absolute difference 17.1% (95% CI 11.6–23.9), p<0.001.
- No significant differences in time to BIS <60, extubation time, ICU stay, or hospital stay.
- Vasoactive use during induction and BIS variation after withdrawal were similar.
Methodological Strengths
- Randomized noninferiority design with prespecified BIS-targeted primary endpoint
- Complete trial completion with high analyzable rate (318/320)
Limitations
- Single-country, relatively short perioperative follow-up limits assessment of rare adverse events
- Sedation success defined by BIS may not capture all clinically relevant aspects (e.g., hemodynamic stability, awareness)
Future Directions: Compare hemodynamic profiles and safety (e.g., hypotension, bradycardia) head-to-head; evaluate outcomes in higher-risk subgroups and assess cost-effectiveness.
BACKGROUND: Remimazolam besylate, despite being widely used in various clinical settings, lacks evidence in cardiac anesthesia. This trial compared its efficacy with propofol in elective cardiac surgery. METHODS: A total of 320 adult patients undergoing elective cardiac surgery via cardiopulmonary bypass between December 2024 and March 2025 were randomized 1:1 to either propofol (1 mg/kg for induction and 1-1.5 mg/kg/h for maintenance) or remimazolam besylate (0.3 mg/kg for induction and 1 mg/kg/h for maintenance) groups. The primary outcome was the sedation success rate (ie, bispectral index 40-60 throughout surgery with predefined dosages and without rescue sedatives), with an absolute difference of 3% as a noninferiority margin. Secondary outcomes included time from drug administration to bispectral index <60 (minute) and bispectral index variation within 15 minutes after drug withdrawal. Application of vasoactive drugs during induction, time to extubation (hour), length of stay in intensive care unit (hour), and hospital (day) were recorded. RESULTS: Of 320 enrolled patients, all patients completed the trial and 318 patients were analyzed eventually. The sedation success rate of the whole surgery was significantly higher in the remimazolam besylate group (159; 99.4%) than in the propofol group (130; 82.3%) (absolute difference 17.1%, 95% confidence interval 11.6%-23.9%; P < .001). No significant differences in time from drug administration to bispectral index <60 (P = .119), bispectral index variation after drug withdrawal (P = .658), time to extubation (P = .824), and length of stay in intensive care unit (P = .898) and hospital (P = .294) were observed. CONCLUSIONS: Remimazolam besylate is noninferior to propofol in terms of sedation efficacy during elective cardiac procedures.